Ticker | Value | Shares | Price | Security | Type | Insider | Title | Return | Flags | Date |
|---|---|---|---|---|---|---|---|---|---|---|
| No transactions found | ||||||||||
Matthew Bennett currently holds 30,552 shares of Bellerophon Therapeutics, Inc. (BLPH), valued at approximately $0. This represents their equity stake as Executive.
Based on SEC Form 4 filings, Matthew Bennett has been a net seller of BLPH stock. They have purchased $0 and sold $546.5K worth of shares.
Matthew Bennett's most recent insider trade was on Jun 21, 2018, when they sold 11,987 shares at $0.00 per share.
Matthew Bennett serves as Executive at Bellerophon Therapeutics, Inc. (BLPH). They have executed 104 insider transactions totaling $546.5K over their tenure at the company.
Matthew Bennett holds the position of Executive at Bellerophon Therapeutics, Inc., where they are responsible for executive-level decision-making and strategic oversight. They have been associated with the company for 20 years and currently hold a stake valued at $0.
Matthew Bennett has shown a selling trading pattern, with $0 in total purchases and $546.5K in total sales across all transactions. Their most recent activity indicates a tendency to reduce their position.
The largest transaction by Matthew Bennett was on Jun 28, 2007, when they sold $2.1M worth of VAS shares. This transaction involved 48,852 shares at $42.75 per share.
Matthew Bennett currently owns 30,552 shares of Bellerophon Therapeutics, Inc. (BLPH), with an estimated value of $0. This stake represents their equity holdings accumulated through purchases, awards, and option exercises.
All of Matthew Bennett's SEC Form 4 insider trading filings are tracked on this page. Each transaction links directly to the official SEC EDGAR filing. Matthew Bennett has 104 Form 4 filings on record as an insider at Bellerophon Therapeutics, Inc..
Set alerts for Matthew Bennett and 40,000+ other insiders.